Display options
Cite
Zhang X, Cai Q, Wang X, et al. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis. 2021;52(3):863-871doi: 10.1007/s11239-021-02415-5.
Zhang, X., Cai, Q., Wang, X., Liao, K., Hu, C., & Chen, H. (2021). Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). Journal of thrombosis and thrombolysis, 52(3), 863-871. https://doi.org/10.1007/s11239-021-02415-5
Zhang, Xin, et al. "Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)." Journal of thrombosis and thrombolysis vol. 52,3 (2021): 863-871. doi: https://doi.org/10.1007/s11239-021-02415-5
Zhang X, Cai Q, Wang X, Liao K, Hu C, Chen H. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis. 2021 Oct;52(3):863-871. doi: 10.1007/s11239-021-02415-5. Epub 2021 Mar 05. PMID: 33674983.
Copy Download .nbib Format: NLM
Share it on

J Thromb Thrombolysis. 2021 Oct;52(3):863-871. doi: 10.1007/s11239-021-02415-5. Epub 2021 Mar 05.

Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE).

Journal of thrombosis and thrombolysis

Xin Zhang, Qiyan Cai, Xiaohui Wang, Ke Liao, Changchun Hu, Hong Chen

Affiliations

  1. Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  2. Chongqing Medical University, Chongqing, China.
  3. Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. [email protected].

PMID: 33674983 DOI: 10.1007/s11239-021-02415-5

Abstract

Venous thromboembolism (VTE), which is characterized by pulmonary embolism and deep vein thrombosis, has become a serious public concern. Notably, over half of the patients with VTE are over 70 years of age, but elderly patients are at high risk of anti-coagulation and bleeding, which increase with age. Moreover, risk factors and frailty also show a difference between elderly patients and ordinary patients diagnosed with VTE. Rivaroxaban is a direct inhibitor of activated factor Xa and has the advantage of predictable pharmacodynamics and pharmacokinetics, no coagulation monitoring, and few drug interactions. As a first-line therapy for VTE, this drug is more advantageous than traditional therapy and exhibits good efficacy and safety for ordinary patients. However, the effectiveness and safety of rivaroxaban in elderly patients have not been fully elucidated. This article reviewed the use of rivaroxaban in elderly patients, including drug interactions, monitoring, reversal agents of rivaroxaban, and the use of small dosages of rivaroxaban in elderly patients.

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Keywords: Deep vein thrombosis; Elderly patients; Pulmonary embolism; Rivaroxaban; Venous thromboembolism

References

  1. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR (2010) Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 10:2105–2112 - PubMed
  2. Sharma M, Cornelius VR, Patel JP et al (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132:194–204 - PubMed
  3. Karamichalakis N, Georgopoulos S, Vlachos K et al (2016) Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol 13:718–723 - PubMed
  4. Spencer FA, Gore JM, Lessard D et al (2008) Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost 100:780–788 - PubMed
  5. Pirmohamed M (2006) Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 62:509–511 - PubMed
  6. Scaglione F (2013) New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 52:69–82 - PubMed
  7. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441–445 - PubMed
  8. Columbus I, Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboem-bolism. N Engl J Med 337:657–662 - PubMed
  9. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE et al (2013) Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thrombo-embolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 11:21 - PubMed
  10. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:956–966 - PubMed
  11. Favaloro EJ, Bonar R, Butler J, Marsden K (2013) Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology 45:435–437 - PubMed
  12. Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN (2013) Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 39:840–846 - PubMed
  13. DeWald TA, Becker RC (2014) The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 37:217–233 - PubMed
  14. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M (2014) Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069, 3069a-3069 - PubMed
  15. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880 - PubMed
  16. The EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510 - PubMed
  17. The EINSTEIN–PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297 - PubMed
  18. International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) (1994) Topic E7 Note for Guidance on Studies to Support of Special Populations: Geriatrics, CPMP/ICH/379/95. London: European Medicine Agency - PubMed
  19. Johnson SA, Eleazer GP, Rondina MT (2016) Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatrics Soc 64(9):1869–1878 - PubMed
  20. Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A, Beinis JY, Gallinari C, Grancher AS, Vincent JP, Naga H, Belmin J, Salvatore R, Kazes M, Pautas E, Boiffin A, Piera JB, Duviquet M, Knafo D, Piau A et al (2004) Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 52:1299–1304 - PubMed
  21. Gaber TA (2005) Significant reduction of the risk of venous thromboembolism in all long-term immobile patients a few months after the onset of immobility. Med Hypotheses 64:1173–1176 - PubMed
  22. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Fallon O, WM, Melton LJ III (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815 - PubMed
  23. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722 - PubMed
  24. Howell MD, Geraci JM, Knowlton AA (2001) Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, casecontrol study. J Clin Epidemiol 54:810–816 - PubMed
  25. Yang CC, Kao CC (2007) Cardiovascular diseases and the risk of venous thromboembolism: a hospital-based case-control study. J Chin Med Assoc 70:103–109 - PubMed
  26. Sellier E, Labarere J, Sevestre MA, Belmin J, Thiel H, Couturier P, Bosson JL (2008) Risk factors for deep vein thrombosis in older patients: a multicenter study with systematic compression ultrasonography in postacute care facilities in France. J Am Geriatr Soc 56:224–230 - PubMed
  27. Kamphuisen PW, Agnelli G, Sebastianelli M (2005) Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 3:1187–1194 - PubMed
  28. Kelly J, Rudd A, Lewis R, Hunt BJ (2001) Venous thromboembolism after acute stroke. Stroke 32:262–267 - PubMed
  29. Erelel M, Cuhadaroglu C, Ece T, Arseven O (2002) The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 96:515–518 - PubMed
  30. Lesser BA, LeeperKV Jr, Stein PD, SaltzmanHA, Chen J, Thompson BT, Hales CA, Popovich J Jr (1992) Greenspan RH,Weg JG. The diagnosis of acute pulmonary embolism in patients with chronic obstructive pulmonary disease. Chest 102:17–22 - PubMed
  31. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a metaanalysis. Circulation 117:93–102 - PubMed
  32. Prandoni P (2009) Venous and arterial thrombosis: two aspects of the same disease? Eur J Intern Med 20:660–661 - PubMed
  33. Song Z-K, Cao H, Wu H, Wei Q, Tang M, Yang S, Liu Y, Qin L (2020) Current status of rivaroxaban in elderly patients with pulmonary embolism. Exp Ther Med 19(4):2817–2825 - PubMed
  34. Gary T, Hafner F, Froehlich H et al (2010) High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients. Acta Haematol 124(4):214–217 - PubMed
  35. Crous-Bou M, Harrington L, Kabrhel C (2016) Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemostasis 8:808–820 - PubMed
  36. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N (2002) Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 71:285–290 - PubMed
  37. Ridker PM, Hennekens CH, Miletich JP (1999) G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99:999–1004 - PubMed
  38. Morley JE, Vellas B, van Kan G, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez RLM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Direct Assoc 14(6):392–397 - PubMed
  39. Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol Biol Med Sci 56:M146–M156 - PubMed
  40. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC (2012) Prevalence of frailty in communitydwelling older persons: a systematic review. J Am Geriatr Soc 60:1487–1492 - PubMed
  41. Ho P, La Brooy B, Hayes L, Lim WK (2015) Direct oral anticoagulants in frail older adults: a geriatric perspective. Semin Thromb Hemostasis 41(4):389–394 - PubMed
  42. Wehinger C, Stollberger C, Langer T, Schneider B, Finsterer J (2001) Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 32:2246–2252 - PubMed
  43. Donze J, Clair C, Hug B et al (2012) Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 125:773–778 - PubMed
  44. Abdelhafiz AH, Wheeldon NM (2008) Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 6:1–11 - PubMed
  45. Coleman CI, Turpie AG, Bunz TJ, Beyer-Westendorf J (2018) Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism. Am J Med 131(8):933–938 - PubMed
  46. Verhamme P, Bounameaux H (2014) Direct oral anticoagulants for acute venous thromboembolism: closing the circle? Circulation 129:725–727 - PubMed
  47. Larsson L, Grimby G, Karlsson J (1979) Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 46:451–456 - PubMed
  48. Migliacci R, Becattini C, Pesavento R, Davi G, Vedovati MC, GuglielminiG, Falcinelli E, Ciabattoni G, Dalla VF, Prandoni P, Agnelli G, Gresele P (2007) Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 92:812–818 - PubMed
  49. Chopard RP, Miranda Neto MH, Biazotto W, Molinari SL (1994) Agerelated changes in the human renal veins and their valves. Ital J Anat Embryol 99:91–101 - PubMed
  50. Brooks EG, Trotman W, Wadsworth MP, Taatjes DJ, Evans MF, Ittleman FP, Callas PW, Esmon CT, Bovill EG (2009) Valves of the deep venous system: an overlooked risk factor. Blood 114:1276–1279 - PubMed
  51. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B (2006) Chronic venous disease. N Engl J Med 355:488–498 - PubMed
  52. Buller HR (2012) Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. Blood 120(21):20–20 - PubMed
  53. Sato D, Ikeda S, Koga S et al (2018) Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age. Heart Vessels 34:678–687 - PubMed
  54. Zhou H, Wei Q, Wu H et al (2019) Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: a case report. Medicine 98(20):e15705 - PubMed
  55. Menichetti M, Rosso S, Menegatti E et al (2015) Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report. J Med Case Rep 9(1):274 - PubMed
  56. Xarelto® [package insert] (2017) Janssen Pharmaceuticals Inc., Titusville - PubMed
  57. Rahimi R, Abdollahi M (2012) An update on the ability of St. John’s wort to affect the metabolism of other drugs. Exp Opin Drug Metab Toxicol 8:691–708 - PubMed
  58. Hennessy M, Kelleher D, Spiers JP et al (2002) St John’s wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75–82 - PubMed
  59. Nutescu E, Chuatrisorn I, Hellenbart E (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31:326–323 - PubMed
  60. Gnoth MJ, Buetehorn U, Muenster U et al (2011) In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 338:372–380 - PubMed
  61. Yasaka M, Lip GY (2014) Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation. Circ J 78:2367–2372 - PubMed
  62. Repplinger DJ, Hoffman RS, Nelson LS, Hines EQ, Howland M, Su MK (2016) Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations. Clin Toxicol 54:647–649 - PubMed
  63. Spiller HA, Mowry JB, Aleguas A, Griffith JR, Goetz R, Ryan ML, Bangh S, Klein-Schwartz W, Schaeffer S, Casavant MJ (2016) An observational study of the factor Xa inhibitors rivaroxaban and apixaban as reported to eight poison centers. Ann Emerg Med 67:189–195 - PubMed
  64. Cuker A, Siegal DM, Crowther MA et al (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128–1139 - PubMed
  65. Helin TA, Pakkanen A, Lassila R et al (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59:807–814 - PubMed
  66. Hillarp A, Baghaei F, Fagerberg Blixter I et al (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9:133–139 - PubMed
  67. Molenaar PJ, Dinkelaar J, Leyte A (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50:1799–1807 - PubMed
  68. Freyburger G, Macouillard G, Labrouche S et al (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127:457–465 - PubMed
  69. Asmis LM, Alberio L, Angelillo-Scherrer A et al (2012) Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 129:492–498 - PubMed
  70. Mani H, Rohde G, Stratmann G et al (2012) Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 108:191–198 - PubMed
  71. Douxfils J, Tamigniau A, Chatelain B et al (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731 - PubMed
  72. Samama MM, Guinet C, Le Flem L et al (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 35:140–146 - PubMed
  73. Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387 - PubMed
  74. Lu G, Lin J, Curnutte JT, Conley PB (2016) Andexanet alfa, a universal antidote under development for factor Xa inhibitors, reverses rivaroxaban-induced inhibition of thrombin generation initiated by the intrinsic coagulation pathway independent of TFPI. Presented at the American Society of Hematology 58th Annual Meeting, San Diego, CA, December 3–6 2016 - PubMed
  75. Lu G, Lin J, Coffey G, Curnutte JT, Conley PB (2015) Interaction of andexanet alfa, a universal antidote to fXA inhibitors, with tissue factor pathway inhibitor enhances reversal of fXA inhibitor-induced anticoagulation. J Thromb Haemost 13:634–635 - PubMed
  76. Crowther M, Gallia L, Genmin L et al (2014) A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 124:A4269 - PubMed
  77. Crowther M, Kitt M, Lorenz T et al (2013) A phase 2 randomized, doubleblind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost 11(suppl 2):201 - PubMed
  78. Crowther M, Vandana M, Kitt M et al (2013) A phase 2 randomized, double-blind, placebo- controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for fXa inhibitors. Blood 122:A3636 - PubMed
  79. Crowther M, Lu G, Conley P et al (2014) Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur Heart J 35(suppl 1):P738 - PubMed
  80. Crowther M, Levy G, Lu G et al (2014) Reversal of enoxaparin-induced anticoagu-lation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect fXa inhibitors—a phase 2 randomized, double-blind, placebo-controlled trial. J Thromb Haemost 12(suppl 1):A1 - PubMed
  81. Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424 - PubMed
  82. ClinicalTrials.gov. A study in patients with acute major bleeding to evaluate the ability of andexanet alfa to reverse the anticoagulation effect of direct and indirect oral anticoagulants. Accessed 29 Feb 2016 - PubMed
  83. Cuker A, Burnett A, Triller D et al (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 94:697–709 - PubMed
  84. January CT, Wann LS, Calkins H et al (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74:104–132 - PubMed
  85. Lip GYH, Banerjee A, Boriani G, Chiang C et al (2018) Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest 154:1121–1201 - PubMed
  86. Connolly SJ, Crowther M, Eikelboom JW et al (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380:1326–1335 - PubMed
  87. Smith MN, Deloney L, Carter C et al (2019) Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thromb 48(2):250–255 - PubMed
  88. Sullivan DW Jr, Gad SC, Laulicht B et al (2015) Nonclinical Safety Assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol 34:308–317 - PubMed
  89. Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141–2142 - PubMed
  90. Rawal A, Ardeshna D, Minhas S et al (2019) Current status of oral anticoagulant reversal strategies: a review. Ann Transl Med 7(17):411 - PubMed
  91. Goodnough LT, Levy JH (2016) The judicious use of recombinant factor VIIa. Semin Thromb Hemost 42:125–132 - PubMed
  92. Perzborn E, Heitmeier S, Laux V, Buchmuller A (2014) Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 133:671–681 - PubMed
  93. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107:253–259 - PubMed
  94. Halim AB, Samama MM, Mendell J (2014) Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res 134:909–913 - PubMed

Publication Types